Skip to main content
PepStack
Blutwerte · Marker

FSH

Follikelstimulierendes Hormon · Follicle-Stimulating Hormone · FSH

Hormone — ReproduktionsachseZeitabhängig
Einheit:
IU/L

FSH quantifies the concentration of follicle-stimulating hormone in the blood, reflecting pituitary function and gonadal activity.

Reference Ranges

Reference
1.512.4IU/L
1.5
12.4
LowNormalHigh
Reference
Unit · IU/L

Ranges vary by sex and age; females have cyclic variations during the menstrual cycle.

Overview

Übersicht

Follicle-stimulating hormone (FSH) is a glycoprotein hormone produced by the anterior pituitary gland. It plays a crucial role in the regulation of the reproductive processes, including the development of ovarian follicles in females and spermatogenesis in males. FSH is a key player in the hypothalamic-pituitary-gonadal axis, influencing the production of sex steroids and gametes. Clinically, FSH levels are indicative of various reproductive and endocrine disorders. Elevated FSH levels can suggest primary gonadal failure, such as in menopause or gonadal dysgenesis, while low levels may indicate secondary hypogonadism due to pituitary dysfunction. FSH is also involved in conditions like polycystic ovary syndrome (PCOS) and can be used to diagnose pituitary adenomas. In the context of athletic performance and biohacking, FSH is less directly relevant but may be monitored in the context of hormonal balance and fertility optimization. Researchers have found that FSH levels can be influenced by factors such as age, sex, and hormonal therapies. Confounding factors include the time of day, as FSH levels can exhibit diurnal variation, and the use of exogenous hormones, which can alter endogenous FSH production. Accurate measurement requires consideration of these variables to avoid misinterpretation.

Klinische Bedeutung

Elevated FSH levels often indicate primary gonadal failure or menopause, while low levels may suggest secondary hypogonadism due to pituitary dysfunction. It is also used in diagnosing and managing reproductive disorders.

Dynamics

Trend Interpretation

Rising Values

Progressively rising FSH levels may indicate advancing ovarian insufficiency or menopause. Re-test in 4-6 weeks if clinically indicated.

Falling Values

Falling FSH levels might suggest recovery from a transient pituitary suppression or response to hormone therapy.

Re-test Interval

4-6 weeks if outside optimal range

Etiology

Causes — High & Low

Cause

Elevated Levels

  • Primary ovarian insufficiency
  • Menopause
  • Gonadal dysgenesis
  • Pituitary adenoma
  • Turner syndrome
Cause

Low Levels

  • Hypothalamic dysfunction
  • Pituitary insufficiency
  • Hyperprolactinemia
  • Exogenous hormone use
  • Severe stress
Protocol

How to Optimize

Lever

Lifestyle

  • Manage stress levels
  • Maintain a healthy weight
  • Regular physical activity
Lever

Nutrition

  • Balanced diet with adequate protein
  • Omega-3 fatty acids
Lever

Supplementation

  • Vitamin D
  • Zinc

Note:

Consult a healthcare provider for personalized advice, especially when considering hormonal therapies.

Testing Guidelines

Fasting Not Required
🕐Time-Sensitive

FSH levels can vary throughout the day; consistency in timing is recommended.

Testing Frequency

Annually for women over 35, or as needed for fertility assessment.

Interfering Factors

  • Hormonal contraceptives
  • Recent hormone therapy
  • Acute illness

Related Peptides & Hormones

Luteinizing Hormone

Correlated with

hormone

Open Research Questions

Current research suggests that robust reference intervals for follicle-stimulating hormone (FSH) in women remain incomplete, particularly in relation to menopausal symptoms and hormone therapy. Researchers have not yet established optimal targets for FSH-blocking therapies in conditions like osteoporosis and Alzheimer's disease. Additionally, unanswered clinical questions include the long-term effects of FSH-blocking antibodies and the implications of elevated FSH levels in functioning gonadotroph adenomas.

21 Research Publications

314

Total Citations

5

Human/RCT

2.0

Avg. Influence

2020

Latest

Sort
Filter
#01

The menopause and aging, a comparative perspective.

ReviewInfluence6.0
130
This review examines the neuroendocrinology of menopause, comparing rodent models to human experiences. It highlights the hormonal changes and their implications, noting that while rodents show hypothalamic impairments affecting LH and FSH surges, similar irreversible changes are not evident in peri-menopausal women.
View on PubMed
#02

Pharmacokinetics of follicle-stimulating hormone: clinical significance.

ReviewInfluence1.0
64
Researchers reviewed the pharmacokinetics of follicle-stimulating hormone (FSH) and its preparations, noting variations in receptor affinity and clearance rates. They highlighted the importance of monitoring FSH levels to optimize treatment outcomes and avoid complications during ovulation induction.
View on PubMed
#03

The follicle-stimulating hormone receptor: a novel target in genitourinary malignancies.

ReviewInfluence1.0
30
Researchers identified the follicle-stimulating hormone receptor (FSHR) as a novel target in genitourinary malignancies, noting its expression in tumor blood vessels and prostate cancer cells. They discussed the potential of targeting FSHR for therapeutic and imaging purposes in cancer treatment.
View on PubMed
#04

FSH-blocking therapeutic for osteoporosis.

Animal
27
Researchers established the follicle-stimulating hormone (FSH) as a target for osteoporosis treatment, demonstrating the efficacy of the FSH-blocking antibody MS-Hu6 in preventing bone loss in mice. The study also confirmed the antibody's safety profile in monkeys, paving the way for future human testing.
View on PubMed
#05

Relationship between metabolic syndrome and follicle-stimulating hormone in postmenopausal women.

UnknownInfluence1.0
19
Researchers examined the relationship between follicle-stimulating hormone (FSH) levels and metabolic syndrome in postmenopausal women. They found that higher FSH levels were associated with better insulin sensitivity and lower incidence of metabolic syndrome, suggesting FSH as a potential biomarker for metabolic health.
View on PubMed
#06

Estrogen Versus FSH Effects on Bone Metabolism: Evidence From Interventional Human Studies.

ReviewInfluence1.0
16
Researchers summarized evidence suggesting that while FSH levels correlate with postmenopausal bone loss, interventional studies have not shown FSH to directly influence bone or fat metabolism in humans. Current data from mouse studies and human observations remain inconclusive.
View on PubMed
#07

A Comprehensive Review of Estradiol, Progesterone, Luteinizing Hormone, and Follicle-Stimulating Hormone in the Context of Laboratory Medicine to Support Women's Health.

Review
9
Researchers reviewed the roles of estradiol, progesterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) in women's health, highlighting the lack of robust reference intervals for these hormones. They discussed the implications of hormone therapy and the need for collaborative efforts to define therapeutic intervals for better women's health outcomes.
View on PubMed
#08

Optimizing a therapeutic humanized follicle-stimulating hormone-blocking antibody formulation by protein thermal shift assay.

In Vitro
5
Researchers optimized a formulation for the humanized FSH-blocking antibody, MS-Hu6, using protein thermal shift assays. They identified optimal buffer conditions and stabilizers that enhanced the antibody's thermal stability, which is crucial for its potential therapeutic use.
View on PubMed
#09

Efficacy and safety of a therapeutic humanized FSH-blocking antibody in obesity and Alzheimer's disease models.

Animal
4
Researchers developed a humanized FSH-blocking antibody, MS-Hu6, which showed protective effects against bone loss, fat gain, and memory loss in mouse models. The study provided evidence for the antibody's safety and efficacy, suggesting potential for treating osteoporosis, obesity, and Alzheimer's disease.
View on PubMed
#10

Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients.

Human
3
Researchers investigated the predictive value of anti-Müllerian hormone (AMH) and FSH levels for ovarian function loss in young breast cancer patients undergoing chemotherapy. They found that baseline AMH levels were predictive of ovarian loss, while the addition of FSH did not improve prediction accuracy.
View on PubMed

Publication Trend

Research publications about FSH over time

8total
1
'95
1
'12
2
'22
1
'24
3
'25

Track your bloodwork in PepStack

Log lab results, track trends and optimize your biomarkers over time.

Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer